Yeleswaram Krishnaswamy 4

What Happened

• Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics (RAPP), sold 10,115 shares on March 25, 2026.
• The weighted-average sale price was $29.99 per share for a total proceeds of approximately $303,355. The reported sale type is "S" (sale), indicating a disposition of shares.

Key Details

• Transaction date: 2026-03-25; filing date: 2026-03-26 (timely filing).
• Price: weighted average $29.99; individual trades ranged from $29.90 to $30.18 (per footnote).
• Shares disposed: 10,115; proceeds ≈ $303,355.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — sale was effected under a Rule 10b5-1 trading plan adopted December 10, 2025. F2 — price is a weighted average; reporting person will provide per-price breakdown on request.
• Transaction code: S = Sale.

Context

• The sale was executed under a pre-established 10b5-1 plan, which typically means the trades were pre-planned and not necessarily a reflection of the insider’s current view of the company.
• For retail investors, purchases often convey more direct insider confidence than scheduled sales; this filing documents a routine, pre-arranged disposition.